- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02809716
High Definition Single Cell Analysis in Colorectal Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the level of correlation between solid tumor touch preparations and liquid biopsies (circulating tumor cells [CTCs]) from patients with surgically resected colorectal cancer (CRC) metastases to the liver using single-cell high-content analysis, including gene copy number variation (CNV) and to establish one or more bio-signatures that represent the liquid and solid biopsy correlation for each patient and for the patient population.
SECONDARY OBJECTIVES:
I. To demonstrate the technical validity and reproducibility of the bio-signatures by comparing the two pre-resection liquid biopsy samples drawn one week prior to and on the day of surgery.
TERTIARY OBJECTIVES:
I. Compare biosignatures between pre-surgical and post-surgical blood samples. II. Compare biosignatures between resected metastatic liver tumor tissue, primary colon tumor tissue (if available), and pre-surgical blood samples.
III. Compare biosignatures between blood samples prior to resection with those obtained after resection and at the time of recurrence.
OUTLINE:
Patients undergo blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. Patients also undergo tissue collection during the surgery. Blood and tissue samples are processed for high definition single cell analysis including whole-genome CNV profiles, protein expression, and cell morphology.
After completion of study, patients are followed up for up to 2 years.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Cancer Center
-
Los Angeles, California, United States, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, United States, 90033
- Los Angeles County-USC Medical Center
-
Newport Beach, California, United States, 92663
- Hoag Memorial Hospital Presbyterian
-
Newport Beach, California, United States, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Able to provide informed consent
Metastatic colorectal adenocarcinoma to the liver (hepatic mCRC)
- Synchronous or metachronous
- Solitary or multifocal
- Concurrent abdominal lymph node metastasis is allowable
- Hepatic mCRC deemed surgically resectable by the study team with plans to undergo surgery
- Has not received any systemic chemotherapy for at least 21 days prior to scheduled hepatic resection
Exclusion Criteria:
- Non-adenocarcinoma metastatic colorectal cancer (e.g. neuroendocrine carcinoma); mucinous component is permitted
- Metastatic CRC that involves organ(s)/tissue(s) other than abdominal lymph nodes and/or liver
- Has received any systemic chemotherapy within 21 days prior to scheduled hepatic resection
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ancillary-Correlative (blood and tumor tissue collection)
Patients undergo collection of blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery.
Patients also undergo and tissue collection during the surgery.
Blood and tissue samples are processed for high definition single cell analysis including, whole-genome CNV profiles, protein expression, and cell morphology.
|
Correlative studies
Undergo collection of blood and tissue samples
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HD-SCA liquid biopsy biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles
Time Frame: Up to 2 years
|
Biosignatures will be compared between cells from tumor tissue within the same patient, cells from blood samples within the same patient, cells from tumor tissue and blood samples within the same patient, cells from tumor tissue and blood samples across different patients.
Upon these comparisons, biosignatures will be established which represent liquid and solid biopsy correlations for each patient and for the patient population.
Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and acr
|
Up to 2 years
|
HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles
Time Frame: Up to 2 years
|
Biosignatures will be compared between cells from tumor tissue within the same patient, cells from blood samples within the same patient, cells from tumor tissue and blood samples within the same patient, cells from tumor tissue and blood samples across different patients.
Upon these comparisons, biosignatures will be established which represent liquid and solid biopsy correlations for each patient and for the patient population.
Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and acr
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles
Time Frame: Up to day 1 of surgery
|
The technical validity and reproducibility of the biosignatures will be demonstrated by comparing two pre-resection liquid biopsy samples.
This reflects a change in the timing of specimen collection from the original protocol.
Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and across patients.
|
Up to day 1 of surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Peter Kuhn, University of Southern California
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3C-15-4 (Other Identifier: USC / Norris Comprehensive Cancer Center)
- P30CA014089 (U.S. NIH Grant/Contract)
- NCI-2016-00736 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IV Colorectal Cancer
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingColorectal Cancer | Colorectal Cancer Stage IV | Stage IV Colorectal Cancer Positive for BRAF V600E MutationUnited States
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditionsUnited States
Clinical Trials on Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCTerminatedLymphoma | Nonneoplastic ConditionUnited States
-
Haukeland University HospitalKarolinska University Hospital; Oslo University Hospital; University Hospital... and other collaboratorsRecruitingSeminoma | Testicular Germ Cell Cancer | Non-Seminoma Testicular Cancer | Stage I Testicular Cancer | Stage II Testicular Cancer | Stage III Testicular Cancer | Stage IV Testicular Cancer | Relapse Testicular CancerNorway, Sweden
-
Centre Hospitalier Universitaire de NīmesCompletedMultiple Sclerosis | Neuromyelitis OpticaFrance
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Completed
-
China National Center for Cardiovascular DiseasesPeking Union Medical College HospitalRecruiting
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedPancreatic CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedGastrointestinal Stromal TumorUnited States